Search

Sanofi SA

Cerrado

SectorSalud

81.04 0.07

Resumen

Variación precio

24h

Actual

Mínimo

80.98

Máximo

81.19

Métricas clave

By Trading Economics

Ingresos

3.9B

5.8B

Ventas

11B

21B

P/B

Media del Sector

15.922

34.393

BPA

1.59

Rentabilidad por dividendo

4.88

Margen de beneficio

27.234

Empleados

82,878

EBITDA

2.2B

2.8B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+33.26% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.88%

2.54%

Próximas Ganancias

24 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-4.1B

100B

Apertura anterior

80.97

Cierre anterior

81.04

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

90 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Sanofi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2025, 10:06 UTC

Principales Movimientos del Mercado

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31 jul 2025, 06:00 UTC

Ganancias

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

30 jul 2025, 10:20 UTC

Ganancias

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

30 jul 2025, 05:31 UTC

Ganancias

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

6 ago 2025, 05:02 UTC

Adquisiciones, fusiones, absorciones

Sanofi Completes the Acquisition of Vigil Neuroscience

6 ago 2025, 05:00 UTC

Adquisiciones, fusiones, absorciones

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 ago 2025, 13:16 UTC

Ganancias

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 12:40 UTC

Ganancias

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 jul 2025, 08:15 UTC

Charlas de Mercado
Ganancias

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 jul 2025, 05:56 UTC

Charlas de Mercado
Ganancias

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 jul 2025, 05:30 UTC

Ganancias

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Business Operating Profit EUR2.46B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Adj EPS EUR1.59

31 jul 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31 jul 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Net Pft EUR3.94B

31 jul 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Sales EUR9.99B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Backs 2025 EPS Adj View

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Narrows 2025 Sales View

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

30 jul 2025, 07:48 UTC

Charlas de Mercado
Ganancias

Santander Results Get Lukewarm Reaction -- Market Talk

30 jul 2025, 06:41 UTC

Charlas de Mercado
Ganancias

Santander's Strategic Investments in Focus -- Market Talk

30 jul 2025, 04:52 UTC

Ganancias

Santander End-2Q CET1 Ratio 13%

Comparación entre iguales

Cambio de precio

Sanofi SA Esperado

Precio Objetivo

By TipRanks

33.26% repunte

Estimación a 12 meses

Media 107.845 EUR  33.26%

Máximo 124 EUR

Mínimo 90 EUR

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

14 ratings

10

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

91.3 / 96.1Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

90 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.